Remdesivir News and Research

RSS

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

The antiviral drug molnupiravir is conditionally recommended for patients with non-severe covid-19 who are at highest risk of hospitalization, says a WHO Guideline Development Group of international experts in The BMJ today.

3 Mar 2022

Assessing the potential of IFNa subtypes in suppressing SARS-CoV-2

A recent study analyzes IFNa subtypes for their therapeutic potential against SARS-CoV-2 and identified the underlying immune signatures and mechanisms.

3 Mar 2022

Adenosine receptor agonists provide therapeutic target in mouse SARS-CoV-2 infection

A new study describes the efficacy of adenosine receptor agonists in the treatment of SARS-CoV-2 infection.

2 Mar 2022

Melatonin as a safe and potentially life-saving treatment for COVID-19

A new study discusses the possible role of melatonin, an antioxidant and anti-inflammatory agent, in treating COVID-19.

24 Feb 2022

Foundational characterization of a new bat-borne ebolavirus and its potential as a human pathogen

Researchers sought to evaluate the zoonotic potential of BOMV to assess the level of risk to public health.

24 Feb 2022

Response of peripheral immune cells to ex vivo SARS-CoV-2 exposure compared to SARS-CoV

Researchers characterized the responses of the PBMCs at the individual cell and cell type levels against SARS-CoV-2 and SARS-CoV ex vivo.

18 Feb 2022

Ensitrelvir, a novel SARS-CoV-2 antiviral

S-217622 reduces the viral load and help alleviate the severity of SARS-CoV-2 in infected hamsters.

17 Feb 2022

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

Researchers select and study an RDV-resistant virus by serial passaging of wild type SARS-CoV-2 in the presence of increasing concentrations of RDV.

15 Feb 2022

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

A new study published demonstrated the in vitro potencies of RDV and GS-441524 through PRA, and nucleoprotein ELISA against SARS-CoV-2 and other VOC/VOIs isolates with specific substitutions in Nsp12.

15 Feb 2022

Researchers identify a powerful combination of antivirals to treat COVID-19

Researchers at the University of Maryland School of Medicine and University of Pennsylvania Perelman School of Medicine have identified a powerful combination of antivirals to treat COVID-19.

14 Feb 2022

Nitazoxanide shows promise for COVID-19 treatment in animal model

In a recent study posted to the bioRxiv* pre-print server, researchers demonstrated that Nitazoxanide (NTZ), an oral drug, broadly inhibits replication of several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in preclinical models of infection.

13 Feb 2022

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

A survey demonstrated that patients with systemic autoimmune rheumatic diseases commonly experience augmented disease severity and disrupted treatment regimens of disease-modifying antirheumatic drugs after acute COVID-19 course.

11 Feb 2022

Properties and pharmacokinetics an oral drug candidate for COVID-19 treatment

Researchers studied the preclinical PK) and in vitro ADME properties of GS-441524, a potential oral drug for COVID-19 treatment.

10 Feb 2022

Wearable devices can help monitor wellness during recovery from COVID-19

Researchers compare the resting heart changes in individuals with COVID-19 with individuals diagnosed with seasonal influenza.

9 Feb 2022

Researchers identify a potent new combination of antiviral drugs to combat SARS-CoV-2

The recent success of Paxlovid has encouraged researchers to develop new anti-covid drugs. With this in mind, scientists from the University of Pennsylvania have been investigating a new synergistic treatment. Their research is released early as an unedited version of the manuscript to be published in the journal Nature.

9 Feb 2022

Remdesivir News and Research

WHO experts suggest antiviral drug for patients with non-severe covid-19 at highest risk of hospitalization

Assessing the potential of IFNa subtypes in suppressing SARS-CoV-2

Adenosine receptor agonists provide therapeutic target in mouse SARS-CoV-2 infection

Melatonin as a safe and potentially life-saving treatment for COVID-19

Foundational characterization of a new bat-borne ebolavirus and its potential as a human pathogen

Response of peripheral immune cells to ex vivo SARS-CoV-2 exposure compared to SARS-CoV

Ensitrelvir, a novel SARS-CoV-2 antiviral

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

Researchers identify a powerful combination of antivirals to treat COVID-19

Nitazoxanide shows promise for COVID-19 treatment in animal model

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

Properties and pharmacokinetics an oral drug candidate for COVID-19 treatment

Wearable devices can help monitor wellness during recovery from COVID-19

Researchers identify a potent new combination of antiviral drugs to combat SARS-CoV-2

Super-resolution imaging of the human coronavirus genome during infection

How SARS-CoV-2 infection progresses throughout the respiratory system

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

UK's most vulnerable will soon be able to access second ground-breaking antiviral

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News